Clinical Research Directory

Inclusion Criteria: * Histologically proven colorectal adenocarcinoma with hepatic metastasis(es) * At least one measurable hepatic metastasis according to the criteria RECIST v1.1 * No other metastatic sites except lung nodules if number ≤ 3 and \< 10 mm * RAS mutation status known (determination of KRAS mutation (exons 2,3 and 4) and determination of the NRAS mutation (exons 2,3 and 4)) * Age ≥ 18 * WHO ≤ 2 (Appendix 4) * No prior treatment by chemotherapy except perioperative or adjuvant chemotherapy discontinued for more than 12 months * Life expectancy \> 3 months * PNN \> 1500/mm3, platelets \> 100 000/mm3, Hb \> 9 g/dLq * Bilirubin \< 25 mmol/L, AST \< 5x ULN, ALT \< 5 x ULN, ALP \< 5 x ULN, TP \> 60%, proteinuria from 24H \< 1 g * Creatinine clearance \> 50 mL/min according to MDRD formula (Appendix 4) * Patient affiliated to a social security scheme * Patient information and signature of the informed consent Exclusion Criteria: * Contraindications specific to the installation of a KTHIA: thrombosis of the hepatic artery, arterial vascular anatomy may compromise a secondary hepatic resection. * Patient immediately eligible for a curative therapy (surgical and/or percutaneous) after discussion in CPR * Following alterations in the 6 months prior to inclusion: myocardial infarction, angina, severe/unstable angina, coronary artery bypass surgery, congestive heart failure NYHA class II, III or IV, stroke or transient ischemic attack * Hypertension not controlled by medical treatment (SBP \> 140 mmHg and/or DBP\> 90 mmHg with blood pressure taken according to the diagram of the HAS) * A history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding in the 6 months preceding the start of treatment * Progressive gastroduodenal ulcer, wound or fractured bone * Abdominal or major extra-abdominal surgery (except diagnostic biopsy) or irradiation in the 4 weeks before starting the treatment * Transplant patients, HIV positive or other immune deficiency syndromes * Any progressive pathology not balanced over the past 6 months: hepatic failure, renal failure, respiratory failure * Peripheral neuropathy \> 1 * Patient with interstitial pneumonitis or pulmonary fibrosis * History of chronic diarrhea or inflammatory disease of the colon or rectum, or unresolved occlusion or sub-occlusion in symptomatic treatment * History of malignant pathologies during the past 5 years except basocellular skin carcinoma considered in complete remission or in situ cervical carcinoma, properly treated * Patient already included in another clinical trial with an experimental molecule * Any known specific contraindication or allergy or hypersensitivity to the drugs used in the study (cf RCP Appendix 7) * Known deficit in DPD * QT/QTc range \> 450 msec for men and \> 470 msec for women * K+ \< LNL, Mg2+ \< LNL, Ca2+ \< LNL * Lack of effective contraception in patients (men and/or women) of childbearing age, pregnant or breastfeeding women, women of childbearing age not having had a pregnancy test * Persons deprived of liberty or under supervision * Impossibility of undergoing medical monitoring during the trial for geographic, social or psychological reasons